Liraglutide meets stricter FDA rules, Novo Nordisk says

03/25/2009 | Bloomberg

Clinical data show liraglutide does not increase heart risks and might even reduce them, leading Novo Nordisk officials to think the firm's diabetes drug will overcome regulatory hurdles that have plagued rival treatments, including Takeda's alogliptin. An FDA panel is set April 2 to evaluate whether liraglutide complies with the agency's new safety guidelines on the cardiovascular effects of diabetes medicines.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC